Cargando…
Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program
AIMS/INTRODUCTION: Biosimilar insulin can reduce treatment costs, although the extent of its use is largely unknown. We examined biosimilar insulin use and its associations with the quality of glycemic control using the Joint Asia Diabetes Evaluation register. MATERIALS AND METHODS: We carried out a...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215931/ https://www.ncbi.nlm.nih.gov/pubmed/29575724 http://dx.doi.org/10.1111/jdi.12843 |
_version_ | 1783368238279688192 |
---|---|
author | Gani, Linsey Lau, Eric Luk, Andrea Sobrepena, Leorino Tran, Quang Khanh Kesavadev, Jothydev Jia, Weiping Yu, Weinan Tsang, Chiu Chi Mukhopadhyay, Monojitketan Jha, Sujeet Sheu, Wayne Ho, Yoon Kun Nguyen, Thy Khue Ozaki, Risa So, Wing Yee Kwan, Christine Fu, Amy W C Mirasol, Roberto Phatak, Sanjeev Ratnakar Kumar, Kanakatte Mylariah Prasanna Aravind, Sosale Janakiraman, Hari Chan, Juliana C N |
author_facet | Gani, Linsey Lau, Eric Luk, Andrea Sobrepena, Leorino Tran, Quang Khanh Kesavadev, Jothydev Jia, Weiping Yu, Weinan Tsang, Chiu Chi Mukhopadhyay, Monojitketan Jha, Sujeet Sheu, Wayne Ho, Yoon Kun Nguyen, Thy Khue Ozaki, Risa So, Wing Yee Kwan, Christine Fu, Amy W C Mirasol, Roberto Phatak, Sanjeev Ratnakar Kumar, Kanakatte Mylariah Prasanna Aravind, Sosale Janakiraman, Hari Chan, Juliana C N |
author_sort | Gani, Linsey |
collection | PubMed |
description | AIMS/INTRODUCTION: Biosimilar insulin can reduce treatment costs, although the extent of its use is largely unknown. We examined biosimilar insulin use and its associations with the quality of glycemic control using the Joint Asia Diabetes Evaluation register. MATERIALS AND METHODS: We carried out a cross‐sectional analysis in 81,531 patients with type 1 and type 2 diabetes enrolled into the Joint Asia Diabetes Evaluation Program from 2007 to 2014. All insulin related terms are extracted from the Joint Asia Diabetes Evaluation portal, and compared clinical profiles between biosimilar and originator insulin users. Multivariate analysis was performed to assess the association of biosimilar insulin compared with originator insulin with dosage, glycated hemoglobin and hypoglycemia events. RESULTS: Amongst 81,531 patients, 20.5% (n = 16,738) were insulin‐treated. In four countries with high use of biosimilar insulin, 4.7% (n = 719) of insulin users (n = 10,197) were treated with biosimilar insulin (India n = 507, 70.3%; the Philippines n = 90, 12.5%; China n = 62, 8.6%; Vietnam n = 60, 8.3%). Biosimilar insulin users were younger and had higher body mass index, glycated hemoglobin, insulin dosage and more frequent hypoglycemia than originator insulin users. These associations were non‐significant after adjustment for confounders. Only age, college education, diabetes education, lipid control, physical activity and history of cardiovascular complications were independently associated with these quality measures. CONCLUSIONS: Biosimilar insulin use is not uncommon in Asia. Data exclusion due to incomplete capturing of brand names suggests possibly higher use. The multiple determinants of the quality of glycemic control call for establishment of prospective cohorts and diabetes registers to monitor the safety and efficacy of different brands of biosimilar insulin and their impacts on clinical outcomes. |
format | Online Article Text |
id | pubmed-6215931 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62159312018-11-08 Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program Gani, Linsey Lau, Eric Luk, Andrea Sobrepena, Leorino Tran, Quang Khanh Kesavadev, Jothydev Jia, Weiping Yu, Weinan Tsang, Chiu Chi Mukhopadhyay, Monojitketan Jha, Sujeet Sheu, Wayne Ho, Yoon Kun Nguyen, Thy Khue Ozaki, Risa So, Wing Yee Kwan, Christine Fu, Amy W C Mirasol, Roberto Phatak, Sanjeev Ratnakar Kumar, Kanakatte Mylariah Prasanna Aravind, Sosale Janakiraman, Hari Chan, Juliana C N J Diabetes Investig Articles AIMS/INTRODUCTION: Biosimilar insulin can reduce treatment costs, although the extent of its use is largely unknown. We examined biosimilar insulin use and its associations with the quality of glycemic control using the Joint Asia Diabetes Evaluation register. MATERIALS AND METHODS: We carried out a cross‐sectional analysis in 81,531 patients with type 1 and type 2 diabetes enrolled into the Joint Asia Diabetes Evaluation Program from 2007 to 2014. All insulin related terms are extracted from the Joint Asia Diabetes Evaluation portal, and compared clinical profiles between biosimilar and originator insulin users. Multivariate analysis was performed to assess the association of biosimilar insulin compared with originator insulin with dosage, glycated hemoglobin and hypoglycemia events. RESULTS: Amongst 81,531 patients, 20.5% (n = 16,738) were insulin‐treated. In four countries with high use of biosimilar insulin, 4.7% (n = 719) of insulin users (n = 10,197) were treated with biosimilar insulin (India n = 507, 70.3%; the Philippines n = 90, 12.5%; China n = 62, 8.6%; Vietnam n = 60, 8.3%). Biosimilar insulin users were younger and had higher body mass index, glycated hemoglobin, insulin dosage and more frequent hypoglycemia than originator insulin users. These associations were non‐significant after adjustment for confounders. Only age, college education, diabetes education, lipid control, physical activity and history of cardiovascular complications were independently associated with these quality measures. CONCLUSIONS: Biosimilar insulin use is not uncommon in Asia. Data exclusion due to incomplete capturing of brand names suggests possibly higher use. The multiple determinants of the quality of glycemic control call for establishment of prospective cohorts and diabetes registers to monitor the safety and efficacy of different brands of biosimilar insulin and their impacts on clinical outcomes. John Wiley and Sons Inc. 2018-04-24 2018-11 /pmc/articles/PMC6215931/ /pubmed/29575724 http://dx.doi.org/10.1111/jdi.12843 Text en © 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Articles Gani, Linsey Lau, Eric Luk, Andrea Sobrepena, Leorino Tran, Quang Khanh Kesavadev, Jothydev Jia, Weiping Yu, Weinan Tsang, Chiu Chi Mukhopadhyay, Monojitketan Jha, Sujeet Sheu, Wayne Ho, Yoon Kun Nguyen, Thy Khue Ozaki, Risa So, Wing Yee Kwan, Christine Fu, Amy W C Mirasol, Roberto Phatak, Sanjeev Ratnakar Kumar, Kanakatte Mylariah Prasanna Aravind, Sosale Janakiraman, Hari Chan, Juliana C N Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program |
title | Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program |
title_full | Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program |
title_fullStr | Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program |
title_full_unstemmed | Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program |
title_short | Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program |
title_sort | cross‐sectional survey of biosimilar insulin utilization in asia: the joint asia diabetes evaluation program |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215931/ https://www.ncbi.nlm.nih.gov/pubmed/29575724 http://dx.doi.org/10.1111/jdi.12843 |
work_keys_str_mv | AT ganilinsey crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT laueric crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT lukandrea crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT sobrepenaleorino crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT tranquangkhanh crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT kesavadevjothydev crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT jiaweiping crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT yuweinan crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT tsangchiuchi crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT mukhopadhyaymonojitketan crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT jhasujeet crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT sheuwayne crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT hoyoonkun crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT nguyenthykhue crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT ozakirisa crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT sowingyee crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT kwanchristine crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT fuamywc crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT mirasolroberto crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT phataksanjeevratnakar crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT kumarkanakattemylariahprasanna crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT aravindsosale crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT janakiramanhari crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT chanjulianacn crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram AT crosssectionalsurveyofbiosimilarinsulinutilizationinasiathejointasiadiabetesevaluationprogram |